pharmaceutical investing Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat
pharmaceutical investing FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher
Prismo Metals Announces Closing of Upsized Private Placement Silver King Exploration to Begin in July